Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque.

10 , 37 Most recently, the REVEAL trial with the CETP inhibitor anacetrapib, the largest trial and the first to go to completion, did show a highly significant reduction in CHD. 23 Although the magnitude of the CHD benefit appeared to correlate with the reduction in non-HDL cholesterol, there are likely wide confidence intervals to the CHD assessments, and a role of increased HDL levels and increased CEC cannot be excluded. 38 Second, Mendelian Randomizat

also in 132,142 other papers

Apart from a weak trend of decreasing CMEC with aging and a modest ( R =0.13) correlation with HDL-C, we did not detect any relationship to covariates.

also in 1,404 other papers